Purpose/Aim: Abnormal activation of signaling pathways related to angiogenesis, inflammation, and oxidative stress has been implicated in the pathophysiology of retinopathy of prematurity (ROP), a leading cause of blindness in pre-term infants. Therapies for ROP include laser and anti-vascular endothelial growth factor agents. However, these therapies have side effects, and even with adequate treatment, visual acuity can be impaired. Novel therapeutic options are needed. Stanniocalcin-1 (STC-1) is a neuroprotective protein with anti-inflammatory and anti-oxidative stress properties. Rodent models of oxygen-induced retinopathy (OIR) were selected to determine whether STC-1 plays a role in the development of OIR.Materials and methods: STC-1 gene and protein expression was first evaluated in the Sprague Dawley rat OIR model that is most similar to human ROP. OIR was then induced in wild-type and Stc-1-/- mice. Retinas were isolated and evaluated for avascular and neovascular area on retinal flat mounts. Quantification of gene expression by quantitative real-time PCR was performed. VEGF was assayed by ELISA in media obtained from induced pluripotent stem-cell-derived retinal pigment epithelial (iPS-RPE) cells following treatment with recombinant STC-1. Results: STC-1 was significantly upregulated in a rat model of OIR compared to room air controls at the gene (P < .05) and protein (P < .001) level. Stc-1-/- OIR mice showed significantly worse ROP compared to wild-type mice as assessed by avascular (20.2 ± 2.4% vs 15.2 ± 2.5%; P = .02) and neovascular area (14.3 ± 2.7% vs 8.8 ± 3.7%; P < .05). Transcript levels of vascular endothelial growth factor-A were significantly higher in Stc-1-/- OIR mice compared to wild-type controls (P = .03). STC-1 reduced VEGF production in iPS-RPE cells (P = .01).Conclusions: STC-1 plays a role in the OIR stress response and development of pathologic vascular features in rodent OIR models by regulating VEGF levels.
Purpose/Aim: Abnormal activation of signaling pathways related to angiogenesis, inflammation, and oxidative stress has been implicated in the pathophysiology of retinopathy of prematurity (ROP), a leading cause of blindness in pre-term infants. Therapies for ROP include laser and anti-vascular endothelial growth factor agents. However, these therapies have side effects, and even with adequate treatment, visual acuity can be impaired. Novel therapeutic options are needed. Stanniocalcin-1 (STC-1) is a neuroprotective protein with anti-inflammatory and anti-oxidative stress properties. Rodent models of oxygen-induced retinopathy (OIR) were selected to determine whether STC-1 plays a role in the development of OIR.Materials and methods: STC-1 gene and protein expression was first evaluated in the Sprague Dawley rat OIR model that is most similar to human ROP. OIR was then induced in wild-type and Stc-1-/- mice. Retinas were isolated and evaluated for avascular and neovascular area on retinal flat mounts. Quantification of gene expression by quantitative real-time PCR was performed. VEGF was assayed by ELISA in media obtained from induced pluripotent stem-cell-derived retinal pigment epithelial (iPS-RPE) cells following treatment with recombinant STC-1. Results:STC-1 was significantly upregulated in a rat model of OIR compared to room air controls at the gene (P < .05) and protein (P < .001) level. Stc-1-/- OIR mice showed significantly worse ROP compared to wild-type mice as assessed by avascular (20.2 ± 2.4% vs 15.2 ± 2.5%; P = .02) and neovascular area (14.3 ± 2.7% vs 8.8 ± 3.7%; P < .05). Transcript levels of vascular endothelial growth factor-A were significantly higher in Stc-1-/- OIR mice compared to wild-type controls (P = .03). STC-1 reduced VEGF production in iPS-RPE cells (P = .01).Conclusions: STC-1 plays a role in the OIR stress response and development of pathologic vascular features in rodent OIR models by regulating VEGF levels.
Entities:
Keywords:
Retinopathy of prematurity; STC-1; Stanniocalcin-1; oxygen induced retinopathy
Authors: Andreas Stahl; Jing Chen; Przemyslaw Sapieha; Molly R Seaward; Nathan M Krah; Roberta J Dennison; Tara Favazza; Felicitas Bucher; Chatarina Löfqvist; Huy Ong; Ann Hellström; Sylvain Chemtob; James D Akula; Lois E H Smith Journal: Am J Pathol Date: 2010-11-05 Impact factor: 4.307
Authors: José Carlos Rivera; Mari Holm; Dordi Austeng; Tora Sund Morken; Tianwei Ellen Zhou; Alexandra Beaudry-Richard; Estefania Marin Sierra; Olaf Dammann; Sylvain Chemtob Journal: J Neuroinflammation Date: 2017-08-22 Impact factor: 8.322
Authors: Gavin W Roddy; Kimberly B Viker; Nelson S Winkler; Cindy K Bahler; Bradley H Holman; David Sheikh-Hamad; Uttio Roy Chowdhury; W Daniel Stamer; Michael P Fautsch Journal: Invest Ophthalmol Vis Sci Date: 2017-05-01 Impact factor: 4.799
Authors: Lindsay S Keir; Rachel Firth; Lyndsey Aponik; Daniel Feitelberg; Susumu Sakimoto; Edith Aguilar; Gavin I Welsh; Anna Richards; Yoshihiko Usui; Simon C Satchell; Valeryia Kuzmuk; Richard J Coward; Jonathan Goult; Katherine R Bull; Ruchi Sharma; Kapil Bharti; Peter D Westenskow; Iacovos P Michael; Moin A Saleem; Martin Friedlander Journal: J Clin Invest Date: 2016-12-05 Impact factor: 14.808
Authors: Gavin W Roddy; Uttio Roy Chowdhury; Kjersten J Anderson; Tommy A Rinkoski; Cheryl R Hann; Vince A Chiodo; W Clay Smith; Michael P Fautsch Journal: PLoS One Date: 2022-05-31 Impact factor: 3.752
Authors: Divya Ail; Marijana Samardzija; Andy C M Chang; Jadwiga Keck; Roger R Reddel; Christian Grimm Journal: Front Neurosci Date: 2022-06-23 Impact factor: 5.152